drugset / Trial / NCT00871767

AZD5672 Bioavailability Study in Healthy Male and Female Subjects

NCT00871767

Phase 1 Completed 24 enrolled AstraZeneca
RandomizedCrossoverOpen-label

Summary

The aim of this study is to compare the blood levels achieved with a new formulation of AZD5672 to an existing formulation of AZD5672 used in previous studies

Timeline

Start
2009-03
Primary completion
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5672 Small molecule 40 mg
Subject AZD5672 Small molecule 100 mg

Indications